Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Klingmann

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Therapeutic Innovation & Regulatory Science|September 22, 2018
ICH: Strengths, Weaknesses, and Future TasksSebastian Specht, Ingrid Klingmann
Frontiers in Pharmacology|March 13, 2020
The Specialist in Medicines Development (SMD) as a Vocational Program in Pharmaceutical Medicine: The Japanese and Italian ExperienceDomenico Criscuolo, Kyoko Imamura, Ingrid Klingmann
Therapeutic Innovation & Regulatory Science|April 26, 2022
A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric PopulationManfred Wargenau, Sibylle Reidemeister, Ingrid Klingmann, et al.
Current Medical Research and Opinion|February 14, 2024
Publishing clinical trial results in plain language: a clash of ethical principles?Avishek Pal, Ingrid Klingmann, Tenzin Wangmo, et al.
Plos One|October 11, 2021
Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sampleJean-Pierre Boissel, David Pérol, Hervé Décousus, et al.
Frontiers in Medicine|October 26, 2018
EUPATI Guidance for Patient Involvement in Medicines Research and Development (R&D); Guidance for Pharmaceutical Industry-Led Medicines R&DKay Warner, Wolf See, David Haerry, et al.
Research Involvement and Engagement|November 30, 2023
Young patients' involvement in a composite endpoint method development on acceptability for paediatric oral dosage formsSibylle Reidemeister, Begonya Nafria Escalera, Daniel Marín, et al.
Human Reproduction (Oxford, England)|February 20, 2020
Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trialHelen Saunders, Cass Khan, Thomas D'Hooghe, et al.
Aging Clinical and Experimental Research|February 2, 2017
SPRINTT and the involvement of stakeholders: strategy and structureRégis Le Lain, Claire Ignaszewski, Ingrid Klingmann, et al.
Pharmaceutics|July 30, 2025
Survey Study to Identify the Maximum Acceptable Numbers of 2 mm and 3 mm Mini-Tablets for Short-, Middle-, and Long-Term Treatments in Acutely and Chronically Sick Children of Different Age Groups Below 18 YearsManfred Wargenau, Eva Mutzke, Lucas-Sebastian Spitzhorn, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Therapeutic Innovation & Regulatory Science|September 22, 2018
ICH: Strengths, Weaknesses, and Future TasksSebastian Specht, Ingrid Klingmann
Frontiers in Pharmacology|March 13, 2020
The Specialist in Medicines Development (SMD) as a Vocational Program in Pharmaceutical Medicine: The Japanese and Italian ExperienceDomenico Criscuolo, Kyoko Imamura, Ingrid Klingmann
Therapeutic Innovation & Regulatory Science|April 26, 2022
A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric PopulationManfred Wargenau, Sibylle Reidemeister, Ingrid Klingmann, et al.
Current Medical Research and Opinion|February 14, 2024
Publishing clinical trial results in plain language: a clash of ethical principles?Avishek Pal, Ingrid Klingmann, Tenzin Wangmo, et al.
Plos One|October 11, 2021
Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sampleJean-Pierre Boissel, David Pérol, Hervé Décousus, et al.
Frontiers in Medicine|October 26, 2018
EUPATI Guidance for Patient Involvement in Medicines Research and Development (R&D); Guidance for Pharmaceutical Industry-Led Medicines R&DKay Warner, Wolf See, David Haerry, et al.
Research Involvement and Engagement|November 30, 2023
Young patients' involvement in a composite endpoint method development on acceptability for paediatric oral dosage formsSibylle Reidemeister, Begonya Nafria Escalera, Daniel Marín, et al.
Human Reproduction (Oxford, England)|February 20, 2020
Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trialHelen Saunders, Cass Khan, Thomas D'Hooghe, et al.
Aging Clinical and Experimental Research|February 2, 2017
SPRINTT and the involvement of stakeholders: strategy and structureRégis Le Lain, Claire Ignaszewski, Ingrid Klingmann, et al.
Pharmaceutics|July 30, 2025
Survey Study to Identify the Maximum Acceptable Numbers of 2 mm and 3 mm Mini-Tablets for Short-, Middle-, and Long-Term Treatments in Acutely and Chronically Sick Children of Different Age Groups Below 18 YearsManfred Wargenau, Eva Mutzke, Lucas-Sebastian Spitzhorn, et al.
Pageof 4